article
Nanobodies that bind a component of the SARS-CoV-2 replication complex
Professors Piergiorgio Percipalle and Gennaro Esposito summarise their study which revealed two nanobodies that could inhibit a non-structural protein of SARS-CoV-2.
List view / Grid view
Proteomics
article
Analysing proteomics data to translate in vivo studies as early as possible
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
article
Drug Target Review – Issue 4 2021
This issue includes articles that discuss the development of long-term 3D tissue cultures from human biopsy samples, the application of flow cytometry in drug discovery and automation for upstream processing in a biologics manufacturing environment. Also included are features on informatics, proteomics and CRISPR.
article
Are computer simulations the future of rapid COVID-19 drug development?
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
article
Improving drug discovery with advanced targeted proteomic monitoring workflows
In this article, Professor Forest White, Department of Biological Engineering at MIT, and Dr Lauren Stopfer, Scientist at BioNTech, present a novel assay approach for the rapid, reproducible and accurate identification of potential therapeutic targets using mass spectrometry.
article
Determining the structure of nanobodies using nuclear magnetic resonance spectroscopy
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
article
An IgM antibody platform to tackle SARS-CoV-2 and its variants
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…
article
Drug Target Review Antibodies ebook 2021
This ebook has features on the development of intranasally-delivered antibodies to combat SARS-CoV-2 and how the structure of a nanobody was determined using nuclear magnetic resonance methods.
video
On-demand webinar: An AI-based approach to phenotypic characterisation of neuronal cells
Evaluation of neurotoxicity effects is an active area of investigation in drug discovery and disease modeling.
news
Researchers discover glycan “gateway” that enables COVID-19 infection
A supercomputing method has revealed details of glycan “gates” on the SARS-CoV-2 Spike protein that open to allow virus entry and infection.
whitepaper
Info kit: Metabolomics in pharmaceutical research
Accelerate the discovery process of new drugs and targets with a better understanding of the metabolome and lipidome during drug development.
whitepaper
Application note: High-content phenotypic profiling using the cell painting assay
The cell painting assay uses up to six fluorescent dyes to label and visualize a variety of subcellular structures at the single cell level.
news
Molecular insights into LSCC may lead to new drug targets
New insights into lung squamous cell carcinoma (LSCC) have emerged from a proteogenomic study, leading to the identification of potential drug targets.
whitepaper
Application note: Measure viral-induced cytopathic effects with a quantitative luminescence assay
Depletion of ATP due to viral-induced CPE leads to a reduction in luminescence signal, enabling quantitation of viral-induced CPE in host cells.
webinar
Utilising synthetic DNA technologies for high-throughput antibody discovery and optimisation
28 July 2021 | By Sartorius AG
In this on-demand webinar, our expert illustrates the utility of GPCR libraries and explains how to discover potent functional antibodies against multiple GPCR targets.
